A new trading day began on Friday, with Revance Therapeutics Inc (NASDAQ: RVNC) stock price down -3.25% from the previous day of trading, before settling in for the closing price of $4.31. RVNC’s price has ranged from $2.30 to $9.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 815.27%. Meanwhile, its annual earnings per share averaged 45.18%. With a float of $95.70 million, this company’s outstanding shares have now reached $104.90 million.
The extent of productivity of a business whose workforce counts for 597 workers is very important to gauge. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.78%, while institutional ownership is 79.61%. The most recent insider transaction that took place on Apr 16 ’24, was worth 9,096. In this transaction Chief Commercial Officer of this company sold 2,392 shares at a rate of $3.80, taking the stock ownership to the 114,864 shares. Before that another transaction happened on Mar 18 ’24, when Company’s President sold 9,211 for $5.04, making the entire transaction worth $46,446. This insider now owns 167,550 shares in total.
Revance Therapeutics Inc (RVNC) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.61 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Here are Revance Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
The latest stats from [Revance Therapeutics Inc, RVNC] show that its last 5-days average volume of 3.51 million was superior to 2.77 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 33.72%. Additionally, its Average True Range was 0.39.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 42.86%, which indicates a significant increase from 31.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 202.90% in the past 14 days, which was higher than the 149.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.41, while its 200-day Moving Average is $4.64. Now, the first resistance to watch is $4.27. This is followed by the second major resistance level at $4.37. The third major resistance level sits at $4.43. If the price goes on to break the first support level at $4.10, it is likely to go to the next support level at $4.04. The third support level lies at $3.94 if the price breaches the second support level.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
With a market capitalization of 423.23 million, the company has a total of 104,902K Shares Outstanding. Currently, annual sales are 234,040 K while annual income is -323,990 K. The company’s previous quarter sales were 59,880 K while its latest quarter income was -38,120 K.
